Familes Blast GSK's New Zofran Label Submission In MDL

Law360, New York (October 6, 2016, 10:21 PM EDT) -- Families in multidistrict litigation over GlaxoSmithKline's anti-nausea drug Zofran on Thursday told a Massachusetts federal court that a 2016 label update shows that it was, in fact, possible to show additional warnings on a previous label beyond what had been approved by regulators, contrary to the company's assertions.

The updated label is "ironically" the first time that a Zofran label has ever disclosed that studies of the drug in pregnancy have reported an increased link between exposure to the drug and cardiovascular and cleft palate birth defects, the families said. GSK had submitted an updated label produced by the new label...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!